Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

ActoGeniX Obtains IND Approval
ActoGeniX, a development stage biopharmaceutical company, announced that the United States÷´ Food and Drug Administration (FDA) has approved the Company÷´s Investigational New Drug (IND) application for AG013, a novel therapeutic product for the treatment of oral mucositis in cancer patients. This IND application approval allows ActoGeniX to initiate a phase 1B clinical trial with AG013, which will now become the second clinical development program in ActoGeniX÷´s portfolio.

Ductal Adenocarcinoma Of The Prostate: Clinical Features And Implications After Local Therapy
UroToday.com - An unspoken and perhaps forgotten enigma of cancer is its relative drug sensitivity. After all, when treated with cytotoxic agents, a tumor may regress while most normal tissues and organs are either left virtually intact or become eventually healed. Only because a tumor rarely gets into a complete remission, and keeps recurring despite treatment, do we consider cancer generally drug-resistant. Does this dichotomy of drug sensitivity versus resistance allude to a secret about cancer"s complex nature and mysterious origin?
News of the day
Novo Nordisk Convenes Policy And Clinical Experts At Diabetes Media Summit
A distinguished panel of clinical and policy experts gathered by Novo Nordisk recently convened in Washington, D.C. to explore solutions to address the exponential growth of diabetes in America. The universal theme from the renowned speakers, including Larry Hausner, CEO of the American Diabetes Association (ADA), was that the cost of the disease to our nation, at $218 billion annually, is startling and the lag in patient motivation to take action to offset the disease is distressing. Without intervention at both a national and patient level, our nation runs the risk of reaching a projected 50 million Americans having diabetes by the year 2025.
Oncology

Nurses: Providing Angioplasty Patient Care In And Out Of The Cath Lab

TCT Symposium will feature strategies for nurses and technologists to improve care for angioplasty patients WHAT: The Cardiovascular Nurse and Technologist Symposium at TCT 2009 will examine the latest advances in interventional, pharmacologic and clinical/administrative strategies for the management of the cardiovascular patient: * Focus on the heart attack patient receiving PCI * Revascularization decisions * Management decisions regarding patients with drug-eluting stents * Leadership * Tough calls in clinical decision-making * Taking charge of your own health WHEN: September 21-22, 2009 WHERE: The Moscone Center, San Francisco, CA WHY: Nurses are on the front lines in and out of the cath lab, providing care for patients with cardiovascular disease, which kills more Americans every year than cancer, making it one of the country"s most significant health risks and a critical health topic for millions of people. This symposium will bring nurses and technologists up to speed on the latest advances in patient care. Featured topics will include: Registered Cardiovascular Invasive Specialists (RCIS) Review Course * Revascularization Decisions in Various Patient Groups (Multivessel Disease, Unprotected Left Main Disease, AMI, etc.) * Improving Door-to-Balloon Times: Translating Research into Practice * Bringing Surgery into the Cath Lab Suite * Elective PCI at Noncardiac Surgery Facilities HOW TO REGISTER: Cardiovascular nurses and technologists may register for the conference at: http://www.tctconference.com/attendee-services/register-now.html Judy Romero Cardiovascular Research Foundation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009